featured
Effect of Denosumab vs Bisphosphonates on Incidence of Type 2 Diabetes, Risk of Foot Ulceration, and All-Cause Mortality in Adults With Osteoporosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis
Diabetes Obes Metab 2024 Jun 20;[EPub Ahead of Print], AE Henney, DR Riley, B O'Connor, TJ Hydes, M Anson, SS Zhao, U Alam, DJ CuthbertsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.